GlassScriptPhysician profile
John M Koostra
NPI 1922058437
$31,639.98
in general payments reported to CMS, 2019-2025
44 companies · $6,946 in 2025
The $6,946 reported for 2025 was more than what 91% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,908 · 2020: $2,924 · 2021: $4,251 · 2022: $4,787 · 2023: $5,835 · 2024: $2,989 · 2025: $6,946.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Consulting Fee: $2,536 · Education: $485.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,749.39 |
| Consulting Fee | $2,536.00 |
| Education | $484.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $4,613.06 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $4,192.66 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Regeneron Healthcare Solutions, INC. | $3,254.44 | 2019-2025 | Dupixent |
| Actelion Pharmaceuticals US, INC. | $2,403.87 | 2019-2025 | Opsumit, Uptravi, Opsynvi |
| Grifols USA, LLC | $2,044.41 | 2019-2023 | Prolastin-C Liquid, Xembify |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,014.76 | 2019-2025 | Ofev, Jascayd |
| Mylan Specialty L.P. | $1,851.55 | 2019-2024 | Yupelri |
| Genzyme Corporation | $1,574.92 | 2019-2025 | |
| Philips North America LLC | $1,173.68 | 2019-2025 | Vest Therapy Und, (8874) Incourage |
| Insmed, INC. | $938.34 | 2019-2025 | Arikayce, Brinsupri |
| Electromed, INC. | $828.83 | 2019-2025 | Smartvest |
| Amgen INC. | $631.44 | 2021-2025 | Tezspire |
| Harmony Biosciences LLC | $625.27 | 2022-2024 | Wakix |
| Merck Sharp & Dohme LLC | $417.49 | 2019-2025 | Winrevair, Recarbrio, Zerbaxa |
| Baxter Healthcare | $413.74 | 2022-2025 | Hillrom - Volara System, Hillrom - Life 2000 Ventilation System, Hillrom - Vest System Model 105 Home Care |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Koostra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.